AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27626285 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute score definition
Number of subjects: 1460
Study 24357510 — intervention group
Group type: EXPERIMENTAL
Intervention: Female Sexual Function Index assessments (quarterly)
Number of subjects: 125
Study 24357510 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual inactivity reported quarterly
Number of subjects: 125
Study 24357510 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for sexual inactivity (reported n=1663)
Number of subjects: 125
Study 24357510 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with sexual life (reported n=1582)
Number of subjects: 125
Study 24357510 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with sexual life when lack of interest cited (reported n=671)
Number of subjects: 125
Study 24357510 — intervention group
Group type: EXPERIMENTAL
Intervention: Interest in learning about treatment for sexual dysfunction
Number of subjects: 125
Study 23579518 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (supplemented with propofol and alfentanil)
Number of subjects: 40
Study 23579518 — intervention group
Group type: COMPARATOR
Intervention: Propofol and alfentanil (supplemented with saline)
Number of subjects: 40
Study 19804956 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein (LP) dietary regimen (protein 0.7 g x kg(‐1) x d(‐1))
Number of subjects: 6
Study 19804956 — intervention group
Group type: COMPARATOR
Intervention: Balanced diet (protein 1g x kg(‐1) x d(‐1))
Number of subjects: 6
Study 18796620 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline sICAM-1 levels
Number of subjects: 1441
Study 16803607 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg
Number of subjects: 20
Study 16803607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12816915 — intervention group
Group type: EXPERIMENTAL
Intervention: Sampling strategies with samples taken at 10/30/90/240 min
Number of subjects: 154
Study 12816915 — intervention group
Group type: EXPERIMENTAL
Intervention: Sampling strategies with samples taken at 10/30/240 min
Number of subjects: 154
Study 12816915 — intervention group
Group type: EXPERIMENTAL
Intervention: Sampling strategies with samples taken at 10/90/240 min
Number of subjects: 154
Study 12816915 — intervention group
Group type: EXPERIMENTAL
Intervention: Sampling strategies with samples taken at 30/90/240 min
Number of subjects: 154
Study 12816915 — intervention group
Group type: EXPERIMENTAL
Intervention: Sampling strategies with samples taken at 90/240 min
Number of subjects: 154
Study 12816915 — intervention group
Group type: EXPERIMENTAL
Intervention: One blood sample at 240 min
Number of subjects: 154
Study 10433305 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia therapy (intracranial temperature 34 degrees C) for 48 hours followed by rewarming at 1 degree C per day for 3 days
Number of subjects: 16
Study 10433305 — intervention group
Group type: COMPARATOR
Intervention: Normothermia therapy (intracranial temperature 37 degrees C) for 5 days
Number of subjects: 16
Study 10433305 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia therapy
Number of subjects: 16
Study 10433305 — intervention group
Group type: COMPARATOR
Intervention: Normothermia therapy
Number of subjects: 16
Study 7717819 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position during submaximal workload (300 kgm.min ± 1)
Number of subjects: 9
Study 7717819 — intervention group
Group type: COMPARATOR
Intervention: Upright and recumbent positions during submaximal workload (300 kgm.min ± 1)
Number of subjects: 9
Study 7717819 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal exercise efforts
Number of subjects: 9
Study 2720131 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectally administered sodium ibuprofen solution
Number of subjects: 8
Study 2720131 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectally administered aluminum ibuprofen suspension
Number of subjects: 8
Study 2720131 — intervention group
Group type: COMPARATOR
Intervention: Orally administered ibuprofen solution
Number of subjects: 8
Study 2720131 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectally administered ibuprofen solution
Number of subjects: 8
Study 1001193 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 40 (4 X 500 ml infusions)
Number of subjects: 192
Study 1001193 — intervention group
Group type: COMPARATOR
Intervention: Control (no dextran)
Number of subjects: 192
Study 1001193 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 40
Number of subjects: 192
Study 31839529 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal laronidase
Number of subjects: 8
Study 31839529 — intervention group
Group type: COMPARATOR
Intervention: Control (no intrathecal laronidase)
Number of subjects: 8
Study 30391226 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (play-based program enhancing executive function skills)
Number of subjects: 92
Study 30391226 — intervention group
Group type: COMPARATOR
Intervention: Control group (focused on dental hygiene, good sleep habits/routines, and physical activity)
Number of subjects: 92
Study 30391226 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (inhibitory control assessment)
Number of subjects: 92
Study 28682422 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pump (IABP) before operation
Number of subjects: 84
Study 28682422 — intervention group
Group type: COMPARATOR
Intervention: Control group underwent IABP after invalidation of internal medicine drug treatment
Number of subjects: 84
Study 25932899 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 20
Study 25932899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 24290333 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-managed computer therapy
Number of subjects: 34
Study 24290333 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 34
Study 22480247 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric rehabilitation service (BRS)
Number of subjects: 0
Study 22480247 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 19196575 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia (EA Group)
Number of subjects: 76
Study 19196575 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA Group)
Number of subjects: 76
Study 17515464 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP > or = 550 pg/mL
Number of subjects: 69
Study 17515464 — intervention group
Group type: COMPARATOR
Intervention: BNP < 550 pg/mL
Number of subjects: 69
Study 17515464 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP > or = 550 pg/mL in patients who underwent valve replacement
Number of subjects: 69
Study 17515464 — intervention group
Group type: COMPARATOR
Intervention: BNP < 550 pg/mL in patients who underwent valve replacement
Number of subjects: 69
Study 17515464 — intervention group
Group type: EXPERIMENTAL
Intervention: Truly severe AS
Number of subjects: 69
Study 17515464 — intervention group
Group type: COMPARATOR
Intervention: Pseudosevere AS
Number of subjects: 69
Study 15155424 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg methylprednisolone acetate mixed with a short acting local anaesthetic
Number of subjects: 18
Study 15155424 — intervention group
Group type: COMPARATOR
Intervention: Short acting local anaesthetic only
Number of subjects: 18
Study 11275935 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected children
Number of subjects: 280
Study 11275935 — intervention group
Group type: COMPARATOR
Intervention: HIV-uninfected children
Number of subjects: 280
Study 9666011 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole daily (200 mg)
Number of subjects: 12
Study 9666011 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole weekly (400 mg)
Number of subjects: 12
Study 9666011 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole treatment
Number of subjects: 12
Study 7983583 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Inoculation Training (SIT) for 20 minutes
Number of subjects: 110
Study 7983583 — intervention group
Group type: COMPARATOR
Intervention: Filler condition
Number of subjects: 110
Study 2955688 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfusion therapy within 2 hours of symptom onset
Number of subjects: 46
Study 2955688 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfusion therapy within 3 hours of symptom onset
Number of subjects: 46
Study 2955688 — intervention group
Group type: EXPERIMENTAL
Intervention: Initially patent arteries
Number of subjects: 46
Study 2955688 — intervention group
Group type: EXPERIMENTAL
Intervention: Patent arteries at follow-up
Number of subjects: 46
Study 31066631 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive expressive writing intervention (writing about a positive memory of the deceased)
Number of subjects: 403
Study 31066631 — intervention group
Group type: COMPARATOR
Intervention: Control group (writing about a recent neutral activity)
Number of subjects: 403
Study 29970054 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program for nurses and supervisors (two-day workshop, posters, pamphlets on patient safety culture)
Number of subjects: 61
Study 29970054 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 61
Study 29970054 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program for nurses and supervisors
Number of subjects: 61
Study 27775830 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 146
Study 27775830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 24016864 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months exercise intervention
Number of subjects: 112
Study 24016864 — intervention group
Group type: COMPARATOR
Intervention: 3 months exercise control group
Number of subjects: 112
Study 24016864 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined groups (exercise intervention and control)
Number of subjects: 112
Study 24016864 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline assessment
Number of subjects: 112
Study 24016864 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-intervention assessment
Number of subjects: 112
Study 24016864 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 112
Study 21357578 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee arthroscopy and an 8-week home exercise programme
Number of subjects: 56
Study 21357578 — intervention group
Group type: COMPARATOR
Intervention: 8-week home exercise programme only
Number of subjects: 56
Study 20435181 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg every other day
Number of subjects: 22071
Study 20435181 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin <150/180 pills/y
Number of subjects: 22071
Study 20435181 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID users >60 days per year
Number of subjects: 22071
Study 20435181 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin >150/180 pills/y and NSAID users <60 days/y
Number of subjects: 22071
Study 20435181 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin <150/180 pills/y and NSAID users >60 days/y
Number of subjects: 22071
Study 19083380 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Probio‐Stick; containing Lactobacillus acidophilus Rosell‐52 and Bifidobacterium longum Rosell‐175, 3 x 10(9) CFU per sachet stick)
Number of subjects: 0
Study 19083380 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sensorially identical without probiotics)
Number of subjects: 0
Study 19694342 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral diet supplements with arginine and fiber (group I)
Number of subjects: 72
Study 19694342 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric, isonitrogenous enteral formula (group II)
Number of subjects: 72
Study 15191344 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg bisoprolol given orally
Number of subjects: 20
Study 15191344 — intervention group
Group type: COMPARATOR
Intervention: Healthy euthyroid controls
Number of subjects: 20
Study 11313089 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (DMI)
Number of subjects: 27
Study 11313089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 9233740 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.2 mg orally and a clonidine TTS-3 patch the evening before surgery and 0.3 mg orally on call to the operating room)
Number of subjects: 40
Study 9233740 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 40
Study 8423228 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic human GIP (0.8 pmol/kg.min over 1 h)
Number of subjects: 18
Study 8423228 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic human GIP (2.4 pmol/kg.min over 1 h)
Number of subjects: 18
Study 8423228 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 [7-36 amide] (0.4 pmol/kg.min over 1 h)
Number of subjects: 18
Study 8423228 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 [7-36 amide] (1.2 pmol/kg.min over 1 h)
Number of subjects: 18
Study 8423228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8423228 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 [7-36 amide]
Number of subjects: 18
Study 8423228 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP
Number of subjects: 18
Study 3103414 — intervention group
Group type: EXPERIMENTAL
Intervention: Supramaintenance infusion (2.77 +/- 0.2 times fasting M, n = 14)
Number of subjects: 24
Study 3103414 — intervention group
Group type: COMPARATOR
Intervention: Submaintenance infusion (1.02 +/- 0.04 times fasting M, n = 6)
Number of subjects: 24
Study 3103414 — intervention group
Group type: COMPARATOR
Intervention: Maintenance infusion (1.39 +/- 0.01 times fasting M, n = 20)
Number of subjects: 24
Study 30738780 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223 (55 kBq/kg) plus abiraterone acetate 1000 mg once daily and prednisone or prednisolone 5 mg twice daily
Number of subjects: 806
Study 30738780 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus abiraterone acetate 1000 mg once daily and prednisone or prednisolone 5 mg twice daily
Number of subjects: 806
Study 30738780 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223
Number of subjects: 806
Study 30738780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 806
Study 28067719 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 118
Study 28067719 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine
Number of subjects: 118
Study 28067719 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir (ABC)
Number of subjects: 118
Study 28067719 — intervention group
Group type: COMPARATOR
Intervention: All study arms
Number of subjects: 118
Study 28067719 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in soluble CD163
Number of subjects: 118
Study 26093743 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural anesthesia
Number of subjects: 0
Study 26093743 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 0
Study 25146061 — intervention group
Group type: EXPERIMENTAL
Intervention: Royal Jelly (1000 mg capsule taken orally once daily for two consecutive menstrual cycles)
Number of subjects: 110
Study 25146061 — intervention group
Group type: COMPARATOR
Intervention: Placebo (capsule taken orally once daily for two consecutive menstrual cycles)
Number of subjects: 110
Study 25146061 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Royal Jelly vs Placebo
Number of subjects: 110
Study 22949478 — intervention group
Group type: EXPERIMENTAL
Intervention: High Framingham Coronary Heart Disease Risk Score (FCRS) (≥20%)
Number of subjects: 3509
Study 22949478 — intervention group
Group type: EXPERIMENTAL
Intervention: Known CHD
Number of subjects: 3509
Study 22949478 — intervention group
Group type: EXPERIMENTAL
Intervention: High FCRS (≥20%)
Number of subjects: 3509
Study 22949478 — intervention group
Group type: COMPARATOR
Intervention: Low/intermediate FCRS (<20%)
Number of subjects: 3509
Study 19570344 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation based on BIS monitor (42 cases)
Number of subjects: 83
Study 19570344 — intervention group
Group type: COMPARATOR
Intervention: Sedation based on subjective scale SAS (41 cases)
Number of subjects: 83
Study 17853755 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment group (Yingxiang (LI 20), Shangyingxiang (EX‐HN 8), Yintang (EX‐HN 3), Hegu (LI 4), Fengchi (GB 20), Dazhui (GV 14), Feishu (BL 13))
Number of subjects: 135
Study 17853755 — intervention group
Group type: COMPARATOR
Intervention: Control group I (Yingxiang (LI 20), Shangyingxiang (EX‐HN 8), Yintang (EX‐HN 3), Hegu (LI 4))
Number of subjects: 135
Study 17853755 — intervention group
Group type: COMPARATOR
Intervention: Control group II (oral administration of Biyankang tablets, 4 tablets each time, thrice each day)
Number of subjects: 135
Study 17853755 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 135
Study 17853755 — intervention group
Group type: EXPERIMENTAL
Intervention: Cured cases of all groups
Number of subjects: 135
Study 15056235 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine
Number of subjects: 0
Study 15056235 — intervention group
Group type: COMPARATOR
Intervention: Control group (age matched children)
Number of subjects: 0
Study 11772242 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem at 2 mg/kg
Number of subjects: 100
Study 11772242 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem at 2 mg/kg
Number of subjects: 100
Study 11772242 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone, cefepime, ceftazidime, cefazolin, cefonicid, cefotaxime, meropenem
Number of subjects: 100
Study 9389782 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroral oestrogen (2 mg oestradiol valerate tablets)
Number of subjects: 79
Study 9389782 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol gel (1g, 1mg oestradiol)
Number of subjects: 79
Study 9389782 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 79
Study 9389782 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 79
Study 7959157 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomeroy's technique with abdominal approach by minilaparotomy and local anesthesia
Number of subjects: 208
Study 3304783 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphonylurea therapy
Number of subjects: 20
Study 3304783 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy
Number of subjects: 20
Study 30348101 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban treatment
Number of subjects: 138
Study 30348101 — intervention group
Group type: COMPARATOR
Intervention: Control group C1
Number of subjects: 138
Study 30348101 — intervention group
Group type: COMPARATOR
Intervention: Control group C2
Number of subjects: 138
Study 26936891 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab plus standard of care (SoC)
Number of subjects: 998
Study 26936891 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab plus SoC
Number of subjects: 998
Study 24996592 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise for 3 days per week for two weeks (Experiment 1)
Number of subjects: 117
Study 24996592 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise for 0, 1, 3, or 5 days per week for two weeks (Experiment 2)
Number of subjects: 117
Study 24996592 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise for 5 days per week for two weeks (Experiment 2)
Number of subjects: 117
Study 24996592 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise treatment (both experiments)
Number of subjects: 117
Study 22814420 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin challenge (placebo-controlled)
Number of subjects: 24
Study 22814420 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during aspirin challenge)
Number of subjects: 24
Study 20881283 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 10
Study 20881283 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 10
Study 20881283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 19031508 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 5 mg/day with alfacalcidol 1 microg/day
Number of subjects: 47
Study 19031508 — intervention group
Group type: COMPARATOR
Intervention: Alfacalcidol group (alfacalcidol 1 microg/day alone)
Number of subjects: 47
Study 16000354 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagrelide plus low-dose aspirin
Number of subjects: 809
Study 16000354 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea plus low-dose aspirin
Number of subjects: 809
Study 12197051 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic HPV vaccine based on the marked immunogenicity and safety of the empty viral capsid
Number of subjects: 40000
Study 12197051 — intervention group
Group type: COMPARATOR
Intervention: Comparison with another vaccine
Number of subjects: 40000
Study 10425010 — intervention group
Group type: EXPERIMENTAL
Intervention: Titration group (n = 20) received protamine doses based on heparin concentration measured by the Hepcon system.
Number of subjects: 34
Study 10425010 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 14) received a fixed dose of protamine (3 mg/kg).
Number of subjects: 34
Study 10425010 — intervention group
Group type: EXPERIMENTAL
Intervention: Titration group (n = 20)
Number of subjects: 34
Study 10425010 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 14)
Number of subjects: 34
Study 7478713 — intervention group
Group type: EXPERIMENTAL
Intervention: MOR-S (7 min)
Number of subjects: 78
Study 7478713 — intervention group
Group type: EXPERIMENTAL
Intervention: MOR-L (11 min)
Number of subjects: 78
Study 7478713 — intervention group
Group type: EXPERIMENTAL
Intervention: FEN-S (5 min)
Number of subjects: 78
Study 7478713 — intervention group
Group type: EXPERIMENTAL
Intervention: FEN-L (8 min)
Number of subjects: 78
Study 7478713 — intervention group
Group type: COMPARATOR
Intervention: Lockout intervals (L and S)
Number of subjects: 78
Study 2207301 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic ibuprofen 200 mg
Number of subjects: 4